anti-SARS-CoV-2 convalescent plasma / Miller School of Medicine, UT Health Science Center, Albert Einstein College of Medicine, NYU Langone Health, Montefiore Health System, Yale University - LARVOL DELTA

Randomized Controlled Trial to Test if Convalescent Plasma Can Treat COVID-19 Disease (University of Miami Miller School of Medicine) - P2, N=360; "Investigators with the Miami Clinical and Translational Science Institute (CTSI) at the University of Miami Miller School of Medicine have launched a phase 2 clinical trial to study if convalescent plasma containing SARS-CoV-2 antibodies is effective in treating COVID-19 positive patients who have been hospitalized with acute respiratory symptoms....'Many clinicians at UHealth have made anecdotal observations of the benefits of convalescent plasma on hospitalized patients with COVID-19 infection, however, this needs to be validated by a well-designed, randomized clinical trial,' said Dushyantha Jayaweera....Plasma treatments with SARS-CoV-2 antibodies may be successful in helping people who are sick with COVID-19 fight the virus. Antibodies are what the body’s immune system makes in response to an infection....Additional study investigators for the Miami sites include site co-lead, Yanyun Wu, M.D..."

Media quote • P2 data